Edition:
United States

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

2.94EUR
26 May 2017
Change (% chg)

€-0.01 (-0.34%)
Prev Close
€2.95
Open
€2.94
Day's High
€2.97
Day's Low
€2.94
Volume
62,931
Avg. Vol
151,960
52-wk High
€3.33
52-wk Low
€1.96

VLS.PA

Chart for VLS.PA

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.93
Market Cap(Mil.): €228.87
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  VLS.PA Industry Sector
P/E (TTM): -- 141.29 17.43
EPS (TTM): -0.66 -- --
ROI: -24.79 2.17 -5.41
ROE: -40.25 0.10 -4.69

BRIEF-Valneva reduces Q1 net loss to 1.7 million euros

* Q1 NET LOSS REDUCED TO €1.7 MILLION ($1.85 million) IN Q1 2017 COMPARED TO A NET LOSS OF €5.0 MILLION IN Q1 2016

May 11 2017

BRIEF-Valneva signs new EB66 commercial license with Bavarian Nordic

* Announces signing of a new EB66 commercial license with Bavarian Nordic

Apr 18 2017

BRIEF-Valneva FY EBITDA turns to profit of EUR 2.8 mln

* Total revenues and grants of 97.9 million euros ($105.64 million) in 2016 (versus 83.3 million euros in 2015)

Mar 23 2017

BRIEF-Valneva revenues and grants increased by 17.5%

* Revenues and grants increased by 17.5% year-on-year and amounted to €97.9 million in 2016 (versus €83.3 million in 2015);

Feb 23 2017

More From Around the Web

Earnings vs. Estimates